Kazia Therapeutics Ltd

NASDAQ:KZIAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.

Contact Information

Headquarters

Three International Towers Level 24 , 300 Barangaroo AvenueSYDNEY, NSW, Australia 2000

Phone

---

Fax

---

Executives

Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director

John Friend

Chief Financial Officer

Karen Krumeich

Clinical & Regulatory Affairs Manager

Lilischkis Kimberley

Chief Business Officer

Peng Leong

Program Director - Degenerative Diseases

Stephen Palmer